.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE43431

« Back to Dashboard

Claims for Patent: RE43431

Title:Quinazoline derivatives and pharmaceutical compositions containing them
Abstract: A compound of general formula I ##STR00001## wherein: R.sub.a is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and R.sub.c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
Inventor(s): Himmelsbach; Frank (Mittelbiberach, DE), Langkopf; Elke (Biberach an der Riss, DE), Blech; Stefan (Warthausen, DE), Jung; Birgit (Laupheim, DE), Baum; Anke (Vienna, AT), Solca; Flavio (Vienna, AT)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:12/542,929
Patent Claims: 1. A compound of formula I ##STR00006## wherein R.sub.a is a .[.benzyl, 1-phenylethyl, or.]. 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylamino.[., N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino.]. group; and R.sub.c is a .[.cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy,.]. tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a stereoisomer or physiologically acceptable salt thereof.

.[.2. The compound of claim 1, wherein Rb is a dimethylamino or a stereoisomer or physiologically acceptable salt thereof..].

.[.3. The compound of formula I according to claim 1, wherein: R.sub.a is a 1-phenylethyl or 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylamino, N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and R.sub.c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetradrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a stereoisomer or physiologically acceptable salt thereof..].

.[.4. The compounds of claim 3, wherein R.sub.b is a dimethylamino, or a stereoisomer or physiologically acceptable salt thereof..].

.[.5. The compounds of claim 3, wherein R.sub.a is a 3-chloro-4-fluorohenyl group and R.sub.b is a dimethylamino group, or a stereoisomer or physiologically acceptable salt thereof..].

.[.6. The compound of formula I according to claim 1, wherein: R.sub.a is a 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylaminno group; and R.sub.c is a tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a steroisomer or physiologically acceptable salt thereof..].

.Iadd.7. The compound of claim 1, wherein: R.sub.c is a tetrahydrofuran-3-yloxy, or a steroisomer or physiologically acceptable salt thereof..Iaddend.

.Iadd.8. 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-o- xo-2-buten-1-yl]amino}-7-((S)-(tetrahydrofuran-3-yl)oxy)quinazoline..Iadde- nd.

.Iadd.9. A physiologically acceptable salt comprising the combination of the compound according to claim 8 with an organic or inorganic acid..Iaddend.

.Iadd.10. The salt according to claim 9 wherein the acid is hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid..Iaddend.

.Iadd.11. The salt according to claim 10, wherein the acid is maleic acid..Iaddend.

.Iadd.12. 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-- oxo-2-buten-1-yl]amino}-7-((R)-(tetrahydrofuran-3-yl)oxy)quinazoline..Iadd- end.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc